New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTPRGO, MYL, VRX, ENDPPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 25, 2015
15:58 EDTVRXZoetis jumps 11%, halted for circuit breaker after report of Valeant approach
Subscribe for More Information
15:57 EDTVRXValeant made preliminary takeover approach to Zoetis, DJ reports
Subscribe for More Information
12:52 EDTMYL, PRGOEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
June 23, 2015
14:16 EDTMYL, PRGOBMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
10:00 EDTPRGOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at BofA/Merrill... Angie's List (ANGI) initiated with a Hold at Topeka... Avenue Financial (AVNU) initiated with an Equal Weight at Stephens... CASI Pharmaceuticals (CASI) initiated with a Buy at H.C. Wainwright... Corindus (CVRS) initiated with a Buy at Stifel... Coupons.com (COUP) initiated with a Market Perform at William Blair... Five Below (FIVE) initiated with an Outperform at RBC Capital... Franklin Financial Network (FSB) initiated with an Equal Weight at Stephens... Galmed (GLMD) initiated with a Buy at H.C. Wainwright... Genesis Healthcare (GEN) initiated with a Neutral at Susquehanna... Groupon (GRPN) initiated with a Hold at Topeka... GrubHub (GRUB) initiated with a Buy at Topeka... Hercules Technology (HTGC) initiated with a Buy at Compass Point... Immersion (IMMR) initiated with a Buy at Craig-Hallum... Lipocine (LPCN) initiated with a Buy at Canaccord... NeoGenomics (NEO) initiated with a Buy at BTIG... Novadaq (NVDQ) initiated with a Neutral at BTIG... Perrigo (PRGO) initiated with an Outperform at BMO Capital... Signal Genetics (SGNL) initiated with a Buy at Chardan... Standard Motor Products (SMP) initiated with a Neutral at CL King... United Community Financial (UCFC) initiated with a Market Perform at Keefe Bruyette... WP Glimcher (WPG) initiated with a Neutral at Goldman... WhiteWave (WWAV) initiated with a Buy at Maxim... Yelp (YELP) initiated with a Buy at Topeka.
09:20 EDTVRXValeant and Progenics announces submission of NDA to FDA for RELISTOR
Valeant Pharmaceuticals International (VRX) and Progenics Pharmaceuticals (PGNX) announced that Valeant submitted a New Drug Application, or NDA, to the FDA for RELISTOR, or methylnaltrexone bromide, Tablets for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
08:49 EDTPRGO, MYLMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
07:25 EDTVRXPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
06:01 EDTMYL, PRGOPerrigo initiated with an Outperform at BMO Capital
BMO Capital analyst David Maris started Perrigo (PRGO) with an Outperform rating and $246 price target. Maris calls shares "significantly undervalued" on a fundamental basis and sees limited downside risk should Mylan (MYL) remove its unsolicited bid for the company.
June 21, 2015
19:53 EDTPRGO, MYLMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
June 19, 2015
08:30 EDTMYLTeva completes purchase of 4.61% interest in Mylan
Subscribe for More Information
05:47 EDTMYLStocks with implied volatility movement; MYLCMG
Subscribe for More Information
June 18, 2015
15:41 EDTMYLTeva tender offer for Mylan likely imminent, says Citi
Citi said Teva (TEVA) is likely to build up a 4.6% stake in Mylan (MYL) by today and that a formal tender offer is likely coming soon. An official bid could come with a provision requiring board changes and a tender will likely trigger a "poison pill" by Mylan, the firm added. Citi has a Buy rating and $70 price target on Teva shares.
11:57 EDTMYLMylan comments on ruling by appeals court on Copaxone patent
Subscribe for More Information
11:54 EDTMYLAppeals court invalidates Teva patent claim related to Copaxone
Subscribe for More Information
10:01 EDTMYLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:46 EDTMYLMylan initiated with a Buy at BTIG
Subscribe for More Information
06:09 EDTMYL, PRGOTeva raises stake in Mylan to 4.3%, Globes reports
Subscribe for More Information
June 17, 2015
11:41 EDTVRXSynergy an 'attractive takeout target' after data, says Cantor
Subscribe for More Information
10:44 EDTVRXSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use